Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M?
- PMID: 32798688
- DOI: 10.1016/j.annonc.2020.07.021
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M?
Conflict of interest statement
Disclosure FF has participated in editorial activities sponsored by BMS and Roche. AL received speakers’ fee from Astra-Zeneca. MT received speakers’ and consultants’ fee from Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, Pierre Fabre; institutional research grants from Astra-Zeneca, Boehringer Ingelheim.
Comment in
-
Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M?Ann Oncol. 2020 Nov;31(11):1582. doi: 10.1016/j.annonc.2020.08.2234. Epub 2020 Sep 2. Ann Oncol. 2020. PMID: 32890631 No abstract available.
Comment on
-
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.Ann Oncol. 2020 Oct;31(10):1397-1404. doi: 10.1016/j.annonc.2020.06.017. Epub 2020 Jul 5. Ann Oncol. 2020. PMID: 32634610 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
